Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Open access
Vergeer, Menno, Holleboom, Adriaan G., Kastelein, John J.P., Kuivenhoven, Jan Albert · 2010 · Journal of Lipid Research

Abstract

There is unequivocal evidence of an inverse association between plasma high-density lipoprotein (HDL) cholesterol concentrations and the risk of cardiovascular disease, a finding that has led to the hypothesis that HDL protects from atherosclerosis. This review details the experimental evidence for this "HDL hypothesis". In vitro studies suggest that HDL has a wide range of anti-atherogenic properties but validation of these functions in humans is absent to date. A significant number of animal studies and clinical trials support an atheroprotective role for HDL; however, most of these findings were obtained in the context of marked changes in other plasma lipids. Finally, genetic studies in humans have not provided convincing evidence that HDL genes modulate cardiovascular risk. Thus, despite a wealth of information on this intriguing lipoprotein, future research remains essential to prove the HDL hypothesis correct.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.r001610

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 181

  1. Barr, 1951, Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions, Am. J. Med., 11, 480, 10.1016/0002-9343(51)90183-0 · DOI · Paper page
  2. 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials, BMJ., 336, 1121, 10.1136/bmj.39548.738368.BE · DOI · Paper page
  3. Hausenloy, 2008, Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels, Heart., 94, 706, 10.1136/hrt.2007.125401 · DOI
  4. Wild, 2008, Time to rethink high-density lipoprotein?, Heart., 94, 692, 10.1136/hrt.2007.126326 · DOI
  5. Hansel, 2006, One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study, Curr. Med. Res. Opin., 22, 1149, 10.1185/030079906X104821 · DOI
  6. Criqui, 1980, Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV70
  7. Hulley, 1977, Plasma high-density lipoprotein cholesterol level. Influence of risk factor intervention, JAMA., 238, 2269, 10.1001/jama.1977.03280220037017 · doi:10.1001/jama.1977.03280220037017
  8. Gnasso, 1984, Acute influence of smoking on plasma lipoproteins, Klin. Wochenschr., 62, 36
  9. Kodama, 2007, Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis, Arch. Intern. Med., 167, 999, 10.1001/archinte.167.10.999 · DOI · Paper page
  10. Rashid, 2007, Effect of obesity on high-density lipoprotein metabolism, Obesity (Silver Spring)., 15, 2875, 10.1038/oby.2007.342 · DOI · Paper page
  11. Busetto, 2004, Short-term effects of weight loss on the cardiovascular risk factors in morbidly obese patients, Obesity (Silver Spring)., 12, 1256
  12. Lann, 2007, Insulin resistance as the underlying cause for the metabolic syndrome, Med. Clin. North Am., 91, 1063, 10.1016/j.mcna.2007.06.012 · DOI · Paper page
  13. Hayek, 1993, Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice, J. Clin. Invest., 92, 1143, 10.1172/JCI116683 · DOI
  14. Tai, 1999, Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia, Diabetes., 48, 1088, 10.2337/diabetes.48.5.1088 · DOI
  15. van Leuven, 2008, Systemic inflammation as a risk factor for atherothrombosis, Rheumatology., 47, 3, 10.1093/rheumatology/kem202 · DOI · Paper page
  16. Khovidhunkit, 2000, Infection and inflammation-induced proatherogenic changes of lipoproteins, J. Infect. Dis., 181, S462, 10.1086/315611 · DOI · Paper page
  17. Heiss, 1980, Plasma high-density lipoprotein cholesterol and socioeconomic status. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV108
  18. Sapolsky, 1987, Social subordinance in wild baboons is associated with suppressed high density lipoprotein-cholesterol concentrations: the possible role of chronic social stress, Endocrinology., 121, 1605, 10.1210/endo-121-5-1605 · DOI
  19. Kontush, 2006, Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis, Pharmacol. Rev., 58, 342, 10.1124/pr.58.3.1 · DOI · Paper page
  20. Fielding, 1982, Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system, Med. Clin. North Am., 66, 363, 10.1016/S0025-7125(16)31425-0 · doi:10.1016/s0025-7125(16)31425-0
  21. Groen, 2001, Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL, J. Clin. Invest., 108, 843, 10.1172/JCI200112473 · doi:10.1172/jci200112473
  22. Alam, 2001, Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice, J. Biol. Chem., 276, 15641, 10.1074/jbc.M010230200 · DOI
  23. deGoma, 2008, Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches, J. Am. Coll. Cardiol., 51, 2199, 10.1016/j.jacc.2008.03.016 · DOI · Paper page
  24. Miettinen, 1989, Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels, Am. J. Clin. Nutr., 49, 629, 10.1093/ajcn/49.4.629 · DOI · Paper page
  25. Gylling, 1992, Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase deficient family, Atherosclerosis., 95, 25, 10.1016/0021-9150(92)90172-D · DOI
  26. Beher, 1983, Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans, Life Sci., 32, 2933, 10.1016/0024-3205(83)90643-4 · doi:10.1016/0024-3205(83)90643-4
  27. El-Harchaoui, 2009, Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia, Atherosclerosis., 207, 614, 10.1016/j.atherosclerosis.2009.06.022 · DOI
  28. Eriksson, 1999, Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans, Circulation., 100, 594, 10.1161/01.CIR.100.6.594 · DOI · Paper page
  29. Nanjee, 2001, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans, J. Lipid Res., 42, 1586, 10.1016/S0022-2275(20)32212-4 · DOI
  30. Brousseau, 2005, Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion, Arterioscler. Thromb. Vasc. Biol., 25, 1057, 10.1161/01.ATV.0000161928.16334.dd · DOI · Paper page
  31. Schwartz, 1978, Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites, J. Clin. Invest., 61, 408, 10.1172/JCI108952 · DOI · Paper page
  32. Turner, 2005, Emerging applications of kinetic biomarkers in preclinical and clinical drug development, Curr. Opin. Drug Discov. Devel., 8, 115
  33. Yvan-Charvet, 2007, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL, Arterioscler. Thromb. Vasc. Biol., 27, 1132, 10.1161/ATVBAHA.106.138347 · DOI · Paper page
  34. Chirinos, 2005, Ability of serum to decrease cellular acylcoA:cholesterol acyl transferase activity predicts cardiovascular outcomes, Circulation., 112, 2446, 10.1161/CIRCULATIONAHA.104.521815 · DOI
  35. Oram, 2000, ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages, J. Biol. Chem., 275, 34508, 10.1074/jbc.M006738200 · DOI · Paper page
  36. Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc. Natl. Acad. Sci. USA., 101, 9774, 10.1073/pnas.0403506101 · DOI · Paper page
  37. Pagler, 2006, SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux, J. Biol. Chem., 281, 11193, 10.1074/jbc.M510261200 · DOI · Paper page
  38. Pirillo, 2006, 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages, Biochim. Biophys. Acta., 1761, 292, 10.1016/j.bbalip.2006.03.009 · DOI
  39. Stangl, 1998, Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low density lipoproteins, and nonlipoprotein cholesterol, J. Biol. Chem., 273, 31002, 10.1074/jbc.273.47.31002 · DOI
  40. Ji, 1997, Scavenger Receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux, J. Biol. Chem., 272, 20982, 10.1074/jbc.272.34.20982 · DOI · Paper page
  41. Wang, 2007, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo, J. Clin. Invest., 117, 2216, 10.1172/JCI32057 · DOI · Paper page
  42. van Dam, 2002, Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study, Lancet., 359, 37, 10.1016/S0140-6736(02)07277-X · DOI · Paper page
  43. Linsel-Nitschke, 2009, Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography, Lipids Health Dis., 8, 14, 10.1186/1476-511X-8-14 · DOI
  44. Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol., 15, 1987, 10.1161/01.ATV.15.11.1987 · DOI · Paper page
  45. Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J. Clin. Invest., 88, 2039, 10.1172/JCI115532 · DOI · Paper page
  46. Moudry, 1997, Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells, Shock., 7, 175, 10.1097/00024382-199703000-00004 · DOI
  47. Navab, 2001, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids, Arterioscler. Thromb. Vasc. Biol., 21, 481, 10.1161/01.ATV.21.4.481 · DOI · Paper page
  48. Lee, 2005, High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity, Atherosclerosis., 183, 251, 10.1016/j.atherosclerosis.2005.03.029 · DOI
  49. Robbesyn, F, Garcia, V, Auge, N, Vieira, O, Frisach, MF, Salvayre, R, Negre-Salvayre, A. 2003. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-κB activation in smooth muscle cells. FASEB J. 02–0240fje. · DOI
  50. Puranik, 2008, Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo, Atherosclerosis., 196, 240, 10.1016/j.atherosclerosis.2007.05.008 · DOI
  51. Nicholls, 2005, Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits, Circulation., 111, 1543, 10.1161/01.CIR.0000159351.95399.50 · DOI · Paper page
  52. Ansell, 2003, Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment, Circulation., 108, 2751, 10.1161/01.CIR.0000103624.14436.4B · DOI · Paper page
  53. Navab, 2001, A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids, J. Lipid Res., 42, 1308, 10.1016/S0022-2275(20)31582-0 · DOI · Paper page
  54. Davies, 1986, Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro, Proc. Natl. Acad. Sci. USA., 83, 2114, 10.1073/pnas.83.7.2114 · DOI · Paper page
  55. Suc, 1997, HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL, Arterioscler. Thromb. Vasc. Biol., 17, 2158, 10.1161/01.ATV.17.10.2158 · DOI · Paper page
  56. Sugano, 2000, High-density lipoproteins protect endothelial cells from tumor necrosis factor-[alpha]-induced apoptosis, Biochem. Biophys. Res. Commun., 272, 872, 10.1006/bbrc.2000.2877 · DOI · Paper page
  57. Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J. Biol. Chem., 276, 34480, 10.1074/jbc.M103782200 · DOI · Paper page
  58. Kimura, 2001, Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells, J. Biol. Chem., 276, 31780, 10.1074/jbc.M104353200 · DOI · Paper page
  59. Kimura, 2003, High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and Its receptors, Arterioscler. Thromb. Vasc. Biol., 23, 1283, 10.1161/01.ATV.0000079011.67194.5A · DOI · Paper page
  60. Chen, 1994, Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets, Life Sci., 55, 1815, 10.1016/0024-3205(94)90092-2 · DOI
  61. Nofer, 2002, HDL and arteriosclerosis: beyond reverse cholesterol transport, Atherosclerosis., 161, 1, 10.1016/S0021-9150(01)00651-7 · DOI · Paper page
  62. Griffin, 1999, High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C, J. Clin. Invest., 103, 219, 10.1172/JCI5006 · DOI · Paper page
  63. Oslakovic, 2009, Anionic phospholipids lose their procoagulant properties when incorporated into high- density lipoproteins, J. Biol. Chem., 284, 5896, 10.1074/jbc.M807286200 · DOI
  64. Deguchi, 2005, High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men, Circulation., 112, 893, 10.1161/CIRCULATIONAHA.104.521344 · DOI · Paper page
  65. Pomp, 2007, Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations, Br. J. Haematol., 139, 289, 10.1111/j.1365-2141.2007.06780.x · DOI · Paper page
  66. Alessi, 2008, Metabolic syndrome, haemostasis and thrombosis, Thromb. Haemost., 99, 995, 10.1160/TH07-11-0682 · DOI · Paper page
  67. Yuhanna, 2001, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat. Med., 7, 853, 10.1038/89986 · DOI · Paper page
  68. Nieuwdorp, 2008, Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus, Diabetologia., 51, 1081, 10.1007/s00125-008-0975-2 · DOI
  69. Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation., 105, 1399, 10.1161/01.CIR.0000013424.28206.8F · DOI · Paper page
  70. Bisoendial, 2003, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein, Circulation., 107, 2944, 10.1161/01.CIR.0000070934.69310.1A · DOI · Paper page
  71. Russell, 2006, Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis, Cardiovasc. Pathol., 15, 318, 10.1016/j.carpath.2006.09.001 · DOI · Paper page
  72. Lusis, 2007, The problem of passenger genes in transgenic mice, Arterioscler. Thromb. Vasc. Biol., 27, 2100, 10.1161/ATVBAHA.107.147918 · DOI
  73. Lichtman, 1999, Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate, Arterioscler. Thromb. Vasc. Biol., 19, 1938, 10.1161/01.ATV.19.8.1938 · DOI · Paper page
  74. Plump, 1999, Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 · DOI · Paper page
  75. Westerterp, 2006, Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice, Arterioscler. Thromb. Vasc. Biol., 26, 2552, 10.1161/01.ATV.0000243925.65265.3c · DOI · Paper page
  76. Li, 1993, Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice, Arterioscler. Thromb., 13, 1814, 10.1161/01.ATV.13.12.1814 · DOI · Paper page
  77. Voyiaziakis, 1998, ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice, J. Lipid Res., 39, 313, 10.1016/S0022-2275(20)33893-1 · DOI
  78. Moore, 2003, Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor, Arterioscler. Thromb. Vasc. Biol., 23, 1914, 10.1161/01.ATV.0000092328.66882.F5 · DOI
  79. Moore, 2005, Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation, Circ. Res., 97, 763, 10.1161/01.RES.0000185320.82962.F7 · DOI · Paper page
  80. Nakamuta, 1998, Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression, Arterioscler. Thromb. Vasc. Biol., 18, 747, 10.1161/01.ATV.18.5.747 · DOI
  81. Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature., 353, 265, 10.1038/353265a0 · DOI · Paper page
  82. Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc. Natl. Acad. Sci. USA., 91, 9607, 10.1073/pnas.91.20.9607 · DOI · Paper page
  83. Paszty, 1994, Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice, J. Clin. Invest., 94, 899, 10.1172/JCI117412 · DOI · Paper page
  84. Liu, 1994, Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice, J. Lipid Res., 35, 2263, 10.1016/S0022-2275(20)39932-6 · DOI
  85. Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in Mice, Circulation., 100, 1816, 10.1161/01.CIR.100.17.1816 · DOI · Paper page
  86. Benoit, 1999, Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models, Circulation., 99, 105, 10.1161/01.CIR.99.1.105 · DOI
  87. Belalcazar, 2003, Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia, Circulation., 107, 2726, 10.1161/01.CIR.0000066913.69844.B2 · DOI
  88. Lebherz, 2007, Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent, Cardiovasc. Diabetol., 6, 15, 10.1186/1475-2840-6-15 · DOI
  89. Miyazaki, 1995, Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits, Arterioscler. Thromb. Vasc. Biol., 15, 1882, 10.1161/01.ATV.15.11.1882 · DOI · Paper page
  90. Duverger, 1996, Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits, Circulation., 94, 713, 10.1161/01.CIR.94.4.713 · DOI · Paper page
  91. Wang, 2003, Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux, Arterioscler. Thromb. Vasc. Biol., 23, 1178, 10.1161/01.ATV.0000075912.83860.26 · DOI · Paper page
  92. Kennedy, 2005, ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation, Cell Metab., 1, 121, 10.1016/j.cmet.2005.01.002 · DOI · Paper page
  93. Out, 2008, Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1, Circ. Res., 102, 113, 10.1161/CIRCRESAHA.107.161711 · DOI · Paper page
  94. Joyce, 2002, The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, Proc. Natl. Acad. Sci. USA., 99, 407, 10.1073/pnas.012587699 · DOI · Paper page
  95. Basso, 2006, Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet, Biochem. Biophys. Res. Commun., 351, 398, 10.1016/j.bbrc.2006.10.044 · DOI
  96. Burgess, 2008, Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 28, 1731, 10.1161/ATVBAHA.108.168542 · DOI
  97. Van Eck, 2006, Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice, Arterioscler. Thromb. Vasc. Biol., 26, 929, 10.1161/01.ATV.0000208364.22732.16 · DOI · Paper page
  98. Curtiss, 2006, Is two out of three enough for ABCG1?, Arterioscler. Thromb. Vasc. Biol., 26, 2175, 10.1161/01.ATV.0000243741.89303.27 · doi:10.1161/01.atv.0000243741.89303.27
  99. Jonas, 2000, Lecithin cholesterol acyltransferase, Biochim. Biophys. Acta., 1529, 245, 10.1016/S1388-1981(00)00153-0 · DOI · Paper page
  100. Lambert, 2001, Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice, J. Biol. Chem., 276, 15090, 10.1074/jbc.M008466200 · DOI
  101. Furbee, 2002, Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice, J. Biol. Chem., 277, 3511, 10.1074/jbc.M109883200 · DOI
  102. Mertens, 2003, Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis, Circulation., 107, 1640, 10.1161/01.CIR.0000056523.08033.9F · DOI · Paper page
  103. Berard, 1997, High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase, Nat. Med., 3, 744, 10.1038/nm0797-744 · DOI · Paper page
  104. Foger, 1999, Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice, J. Biol. Chem., 274, 36912, 10.1074/jbc.274.52.36912 · DOI · Paper page
  105. Mehlum, 1997, Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis, APMIS., 105, 861, 10.1111/j.1699-0463.1997.tb05095.x · DOI
  106. Mehlum, 2000, Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis, APMIS., 108, 336, 10.1034/j.1600-0463.2000.d01-65.x · DOI
  107. Furbee, 2002, Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition, Atherosclerosis., 165, 89, 10.1016/S0021-9150(02)00201-0 · DOI
  108. Hoeg, 1996, Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis, Proc. Natl. Acad. Sci. USA., 93, 11448, 10.1073/pnas.93.21.11448 · DOI · Paper page
  109. Brousseau, 1997, Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner, J. Lipid Res., 38, 2537, 10.1016/S0022-2275(20)30038-9 · DOI
  110. Brousseau, 2000, LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits, Arterioscler. Thromb. Vasc. Biol., 20, 450, 10.1161/01.ATV.20.2.450 · DOI
  111. Marotti, 1993, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein, Nature., 364, 73, 10.1038/364073a0 · DOI · Paper page
  112. Plump, 1999, Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 · DOI · Paper page
  113. de Haan, 2008, Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin, Circulation., 117, 2515, 10.1161/CIRCULATIONAHA.107.761965 · DOI
  114. Herrera, 1999, Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein, Nat. Med., 5, 1383, 10.1038/70956 · DOI
  115. Hayek, 1995, Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene, J. Clin. Invest., 96, 2071, 10.1172/JCI118255 · DOI · Paper page
  116. Harder, 2007, Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice, Arterioscler. Thromb. Vasc. Biol., 27, 858, 10.1161/01.ATV.0000259357.42089.dc · DOI
  117. Huang, 2002, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia, Clin. Sci. (Lond.)., 103, 587, 10.1042/cs1030587 · DOI
  118. Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature., 406, 203, 10.1038/35018119 · DOI · Paper page
  119. Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 2106, 10.1161/01.ATV.20.9.2106 · DOI · Paper page
  120. Sugano, 1998, Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits, J. Biol. Chem., 273, 5033, 10.1074/jbc.273.9.5033 · DOI · Paper page
  121. Morehouse, 2007, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet- induced atherosclerosis in New Zealand White rabbits, J. Lipid Res., 48, 1263, 10.1194/jlr.M600332-JLR200 · DOI · Paper page
  122. Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science., 271, 518, 10.1126/science.271.5248.518 · DOI · Paper page
  123. Rigotti, 1997, A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism, Proc. Natl. Acad. Sci. USA., 94, 12610, 10.1073/pnas.94.23.12610 · DOI · Paper page
  124. Braun, 2002, Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice, Circ. Res., 90, 270, 10.1161/hh0302.104462 · DOI · Paper page
  125. Kozarsky, 2000, Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse, Arterioscler. Thromb. Vasc. Biol., 20, 721, 10.1161/01.ATV.20.3.721 · DOI · Paper page
  126. Covey, 2003, Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells, Arterioscler. Thromb. Vasc. Biol., 23, 1589, 10.1161/01.ATV.0000083343.19940.A0 · DOI · Paper page
  127. van Eck, 2004, Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development, Am. J. Pathol., 165, 785, 10.1016/S0002-9440(10)63341-X · DOI · Paper page
  128. McCoy, 2002, Characterization of the lipolytic activity of endothelial lipase, J. Lipid Res., 43, 921, 10.1016/S0022-2275(20)30466-1 · DOI · Paper page
  129. Ehnholm, 1975, Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids, J. Biol. Chem., 250, 6756, 10.1016/S0021-9258(19)40996-4 · DOI · Paper page
  130. Busch, 1994, Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice, J. Biol. Chem., 269, 16376, 10.1016/S0021-9258(17)34018-8 · DOI
  131. Dichek, 2004, Divergent effects of the catalytic and bridging functions of hepatic lipase on atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 24, 1696, 10.1161/01.ATV.0000135981.61827.9d · DOI
  132. Freeman, 2007, Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice, J. Lipid Res., 48, 104, 10.1194/jlr.M600321-JLR200 · DOI
  133. Gonzalez-Navarro, 2004, The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice, J. Biol. Chem., 279, 45312, 10.1074/jbc.M406495200 · DOI
  134. Barcat, 2006, Combined hyperlipidemia/hyperalphalipoproteinemia associated with premature spontaneous atherosclerosis in mice lacking hepatic lipase and low density lipoprotein receptor, Atherosclerosis., 188, 347, 10.1016/j.atherosclerosis.2005.11.022 · DOI
  135. Ishida, 2004, Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice, J. Biol. Chem., 279, 45085, 10.1074/jbc.M406360200 · DOI
  136. Ko, 2005, Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE−/− and LDLR−/− mice, J. Lipid Res., 46, 2586, 10.1194/jlr.M500366-JLR200 · DOI
  137. Tall, 2002, Regulation and mechanisms of macrophage cholesterol efflux, J. Clin. Invest., 110, 899, 10.1172/JCI0216391 · DOI · Paper page
  138. Schuster, 2002, Accumulation of foam cells in liver X receptor-deficient mice, Circulation., 106, 1147, 10.1161/01.CIR.0000026802.79202.96 · DOI · Paper page
  139. Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proc. Natl. Acad. Sci. USA., 99, 7604, 10.1073/pnas.112059299 · DOI · Paper page
  140. Levin, 2005, Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists, Arterioscler. Thromb. Vasc. Biol., 25, 135, 10.1161/01.ATV.0000150044.84012.68 · DOI · Paper page
  141. Tangirala, 2002, Identification of macrophage liver X receptors as inhibitors of atherosclerosis, Proc. Natl. Acad. Sci. USA., 99, 11896, 10.1073/pnas.182199799 · DOI · Paper page
  142. Schultz, 2000, Role of LXRs in control of lipogenesis, Genes Dev., 14, 2831, 10.1101/gad.850400 · DOI · Paper page
  143. Grefhorst, 2002, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles, J. Biol. Chem., 277, 34182, 10.1074/jbc.M204887200 · DOI · Paper page
  144. Davies, 2008, Effects of the synthetic liver X receptor agonist T0901317 on the growth hormone and thyroid hormone axes in male rats, Endocrine., 33, 196, 10.1007/s12020-008-9067-9 · DOI
  145. Schaefer, 1980, Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease), Ann. Intern. Med., 93, 261, 10.7326/0003-4819-93-2-261 · DOI · Paper page
  146. Clee, 2000, Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes, J. Clin. Invest., 106, 1263, 10.1172/JCI10727 · DOI · Paper page
  147. Hovingh, 2005, Compromised LCAT function is associated with increased atherosclerosis, Circulation., 112, 879, 10.1161/CIRCULATIONAHA.105.540427 · DOI · Paper page
  148. Hovingh, 2004, A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease, J. Am. Coll. Cardiol., 44, 1429, 10.1016/j.jacc.2004.06.070 · DOI
  149. Karathanasis, 1983, An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis, Nature., 301, 718, 10.1038/301718a0 · DOI
  150. Miller, 2007, Do mutations causing low HDL-C promote increased carotid intima-media thickness?, Clin. Chim. Acta., 377, 273, 10.1016/j.cca.2006.10.001 · DOI
  151. Hong, 2002, Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T, Clin. Chem., 48, 2066, 10.1093/clinchem/48.11.2066 · DOI
  152. Chiesa, 2003, Apolipoprotein A-I(Milano): current perspectives, Curr. Opin. Lipidol., 14, 159, 10.1097/00041433-200304000-00007 · DOI
  153. Weibel, 2007, Wild-type apoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux, Arterioscler. Thromb. Vasc. Biol., 27, 2022, 10.1161/ATVBAHA.107.148403 · DOI
  154. Sirtori, 2008, Viability of developing CETP inhibitors, Cardiovasc. Ther., 26, 135, 10.1111/j.1527-3466.2008.00049.x · DOI
  155. Klos, 2007, Genetic determinants of HDL: monogenic disorders and contributions to variation, Curr. Opin. Cardiol., 22, 344, 10.1097/HCO.0b013e3281a8acad · DOI
  156. Edmondson, 2009, Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans, J. Clin. Invest., 119, 1042
  157. Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA., 299, 2524, 10.1001/jama.299.21.2524 · DOI · Paper page
  158. Johannsen, 2009, Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease, J. Clin. Endocrinol. Metab., 94, 1264, 10.1210/jc.2008-1342 · DOI
  159. Thompson, 2008, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk, JAMA., 299, 2777, 10.1001/jama.299.23.2777 · DOI · Paper page
  160. Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA., 285, 1585, 10.1001/jama.285.12.1585 · DOI · Paper page
  161. Saha, 2007, The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials, Am. Heart J., 154, 943, 10.1016/j.ahj.2007.07.011 · DOI
  162. Kamanna, 2008, Nicotinic acid: recent developments, Curr. Opin. Cardiol., 23, 393, 10.1097/HCO.0b013e3283021c82 · DOI
  163. van der Hoorn, 2008, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice, Arterioscler. Thromb. Vasc. Biol., 28, 2016, 10.1161/ATVBAHA.108.171363 · DOI · Paper page
  164. Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation., 110, 3512, 10.1161/01.CIR.0000148955.19792.8D · DOI · Paper page
  165. Taylor, 2006, The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3, Curr. Med. Res. Opin., 22, 2243, 10.1185/030079906X148508 · DOI · Paper page
  166. Taylor, 2009, Extended-release niacin or ezetimibe and carotid intima-media thickness, N. Engl. J. Med., 361, 2113, 10.1056/NEJMoa0907569 · DOI · Paper page
  167. Rader, 2003, High-density lipoproteins as an emerging therapeutic target for atherosclerosis, JAMA., 290, 2322, 10.1001/jama.290.17.2322 · DOI
  168. Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA., 297, 1675, 10.1001/jama.297.15.jpc70004 · DOI · Paper page
  169. Tall, 2007, CETP inhibitors to increase HDL cholesterol levels, N. Engl. J. Med., 356, 1364, 10.1056/NEJMe078029 · DOI
  170. de Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study, Circulation., 105, 2159, 10.1161/01.CIR.0000015857.31889.7B · DOI · Paper page
  171. Krishna, 2007, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet., 370, 1907, 10.1016/S0140-6736(07)61813-3 · DOI · Paper page
  172. Bots, 2007, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial, Lancet., 370, 153, 10.1016/S0140-6736(07)61088-5 · DOI · Paper page
  173. Kastelein, 2007, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia, N. Engl. J. Med., 356, 1620, 10.1056/NEJMoa071359 · DOI · Paper page
  174. Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635 · DOI · Paper page
  175. Vergeer, 2008, Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials, Circulation., 118, 2515, 10.1161/CIRCULATIONAHA.108.772665 · DOI
  176. Vergeer, 2009, The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors, Am. J. Cardiol., 104, 32E, 10.1016/j.amjcard.2009.09.017 · DOI
  177. Forrest, 2008, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone, Br. J. Pharmacol., 154, 1465, 10.1038/bjp.2008.229 · DOI · Paper page
  178. Navab, 2005, Apolipoprotein A-I mimetic peptides, Arterioscler. Thromb. Vasc. Biol., 25, 1325, 10.1161/01.ATV.0000165694.39518.95 · DOI · Paper page
  179. Bloedon, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients, J. Lipid Res., 49, 1344, 10.1194/jlr.P800003-JLR200 · DOI · Paper page
  180. Navab, 2008, Apo A-1 mimetic peptides as atheroprotective agents in murine models, Curr. Drug Targets., 9, 204, 10.2174/138945008783755584 · DOI
  181. Krimbou, 2007, Abstract 679: oral administration of compound RVX-208 increases serum levels of apoA-I and improves high-density lipoprotein-mediated cholesterol efflux in african green monkeys, Circulation., 116, II

Cited by

Metadata

Authors
Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2010-08
Volume
51
Issue
8
Pages
2058-2073
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2117622925
Cited by
220
References
27
FWCI
18.94
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.